World J Gastroenterol. Jun 28, 2014; 20(24): 7525-7533 Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7525
Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations
Alfredo Guglielmi, Andrea Ruzzenente, Simone Conci, Alessandro Valdegamberi, Marco Vitali, Francesca Bertuzzo, Michela De Angelis, Guido Mantovani, Calogero Iacono, Department of Surgery, Division of General Surgery A, Unit of Hepato-Pancreatico-Biliary surgery, University of Verona Medical School, 37134 Verona, Italy
ORCID number: $[AuthorORCIDs]
Author contributions: Guglielmi A, Ruzzenente A and Iacono C designed the research and supervised the paper; Ruzzenente A, Conci S and Valdegamberi A wrote the paper; Conci S, Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M and Mantovani G performed the literature research; Iacono C and Guglielmi A provided critical expertise and reviewed the paper.
Correspondence to: Calogero Iacono, Professor, Department of Surgery, Division of General Surgery A, Unit of Hepato-Pancreatico-Biliary surgery, University of Verona Medical School, University Hospital “GB Rossi”, P.le L.A. Scuro, 37134 Verona, Italy. calogero.iacono@univr.it
Telephone: +39-45-8124412 Fax: +39-45-8027426
Received: November 20, 2013 Revised: January 17, 2014 Accepted: March 19, 2014 Published online: June 28, 2014 Processing time: 218 Days and 15.4 Hours
Abstract
The barcelona clinic liver cancer (BCLC) staging system has been approved as guidance for hepatocellular carcinoma (HCC) treatment guidelines by the main Western clinical liver associations. According to the BCLC classification, only patients with a small single HCC nodule without signs of portal hypertension or hyperbilirubinemia should undergo liver resection. In contrast, patients with intermediate-advanced HCC should be scheduled for palliative therapies, even if the lesion is resectable. Recent studies report good short-term and long-term outcomes in patients with intermediate-advanced HCC treated by liver resection. Therefore, this classification has been criticised because it excludes many patients who could benefit from curative resection. The aim of this review was to evaluate the role of surgery beyond the BCLC recommendations. Safe liver resection can be performed in patients with portal hypertension and well-compensated liver function with a 5-year survival rate of 50%. Surgery also offers good long-term result in selected patients with multiple or large HCCs with a reported 5-year survival rate of over 50% and 40%, respectively. Although macrovascular invasion is associated with a poor prognosis, liver resection provides better long-term results than palliative therapies or best supportive care. Recently, researchers have identified several genes whose altered expression influences the prognosis of patients with HCC. These genes may be useful for classifying the biological behaviour of different tumours. A revision of the BCLC classification should be introduced to provide the best treatment strategy and to ensure the best prognosis in patients with HCC.
Core tip: The present review reports the results of surgery beyond the barcelona clinic liver cancer recommendations. Recent studies have reported that surgical resection can result in good short- and long-term survival in patients with early hepatocellular carcinoma (HCC) with portal hypertension and in patients with intermediate-advanced HCC. A careful preoperative evaluation, including liver function and remnant volume assessment, is mandatory before liver resection in HCC patients. An understanding of the biological behaviour of these tumours through molecular biology studies may be useful in choosing the optimal treatment strategy.
Citation: Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M, Mantovani G, Iacono C. Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol 2014; 20(24): 7525-7533
Hepatocellular carcinoma (HCC) is ranked as the sixth most common cancer and the third leading cause of cancer-related deaths worldwide[1]. The incidence of HCC is rising in Western countries, likely as a result of the epidemic incidence of chronic liver disease and, more recently, as a result of hepatopathy related to metabolic syndrome[2-5]. Curative treatments, including liver transplantation, surgical resection or percutaneous ablation, are able to achieve a long-term survival of more than 50% at 5 years; however, only a small group of patients with early-stage HCC are eligible for these therapies[6-11]. Despite the increased frequency of surveillance programs, in Western countries, the majority of patients have an advanced HCC at diagnosis.
Thus, in the past decades, several HCC staging systems based on tumour burden and liver function have been proposed to guide therapeutic decisions[12-17]. The barcelona clinic liver cancer (BCLC) staging system has been validated by Western and Eastern groups[18-20] and has been approved as guidance for HCC treatment algorithms by the European Association for the Study of Liver (EASL), the European Organization of Research and Treatment of Cancer (EORTC) and the American Association for the Study of Liver Disease (AASLD), but not by the main Asian associations for the study of liver diseases[21-23]. This staging system currently recommends curative treatments for very early- or early-stage HCC (BCLC stage 0-A), palliative therapies such as transarterial chemoembolisation (TACE) for intermediate-stage HCC (BCLC stage B), sorafenib administration for advanced-stage HCC (BCLC stage C), and supportive care for end-stage HCC (BCLC stage D)[24]. According to the BCLC classification, liver resection should be performed only in patients with a small single HCC nodule without signs of portal hypertension or hyperbilirubinemia.
According to recent surgical series, the 5-year overall survival rate after liver resection ranges from 61% to 91% with postoperative mortality approaching 0%[25,26]. Based on the BCLC classification, patients with multiple, large and macrovascular invasive HCC should undergo palliative treatments with unsatisfactory long terms results even if the lesion is resectable[27-29]. However, recent studies have reported that surgical resection can lead to good short- and long-term survival in these patients[30-33]. Therefore, this classification has been criticised because it excludes many patients who could benefit from curative resection[34-37]. The aim of this review is to evaluate the role of surgery beyond the BCLC recommendations.
BCLC 0-A HCC WITH PORTAL HYPERTENSION (RECOMMENDED LIVER TRANSPLANTATION OR PERCUTANEOUS ABLATION)
According to the BCLC classification, the best treatment for BCLC 0-A HCC patients with portal hypertension (PH) is liver transplantation[24,38-40], which involves the resection of the entire potentially tumour-bearing liver and the removal of underlying liver disease. However, the limited availability of donors, high costs, and long wait period increases the demand for alternative treatment strategies for early HCC with portal hypertension.
The surgical indications for HCC patients with PH remain a matter of debate. Portal hypertension is associated with a high risk of postoperative liver failure[41]. Thus, it is consider a contraindication to surgery in the EASL/EORTC/AALSD guidelines[21,22,24]. In Eastern countries, however, PH is not considered a contraindication to liver resection due to the low rates of postoperative mortality and morbidity that can be achieved if a careful preoperative liver function evaluation is performed[12,42]. Nevertheless, several Western authors have also advocated for liver resection in cases of HCC with PH[43-45]. In recent years, authors have reported mortality and morbidity rates from 0.5% to 4.5% and 38% to 43%, respectively, in patients with PH and from 0.0% to 6.1% and 34.8% to 38.5%, respectively, in patients without PH. Considering long-term outcomes, the 5-year overall survival rates after liver resection varies from 48% to 51.5% in patients with PH and from 61.5% to 65% in patients without PH[44,45].
Similar results were reported in 2011 by Ruzzenente _et al_[46]. In fact, in a surgical series of 44 HCC patients with PH, the postoperative mortality and morbidity were of 4.6% and 37%, respectively, and the 3- and 5-year overall survival rates were 48.7% and 44.9%, respectively. Furthermore, the authors evaluated the prognostic value of the relationship between the extent of liver resection and PH in Child-Pugh A patients. In patients who underwent limited liver resection (wedge or one segment), no significant differences were found between patients with or without PH, and the 5-year survival rates were 72.4% and 61.4%, respectively (P = 0.458)[46] (Table 1).
Table 1 Results of liver resection in a recently published surgical series (after 2005) in which surgery was performed beyond the beyond barcelona clinic liver cancer recommendations.
Many studies have compared the survival rates between percutaneous ablation and liver resection for BCLC A HCC patients[47]. In patients with early HCC (single nodule larger than 2 cm), the survival rates are higher after surgery than after percutaneous ablation[11,48,49]. In patients with very early HCC (single nodule ≤ 2 cm), the long-term results of percutaneous ablation are comparable to liver resection, but percutaneous ablation is less invasive[49,50]. Therefore, portal hypertension should not be considered an absolute contraindication to limited liver resection in BCLC 0-A HCC patients with well-compensated liver function.
BCLC A-B MULTIPLE HCCS NOT SUITABLE FOR LIVER TRANSPLANTATION (RECOMMENDED PERCUTANEOUS ABLATION OR TACE)
Liver resection in the presence of multiple HCCs is still controversial[51,52]. According to BCLC, all patients with multiple HCCs should be scheduled for percutaneous ablation or TACE if liver transplantation is contraindicated[24].
Despite the guidelines, in the literature there are several surgical series that include patients with multiple HCCs with 5-year survival rates varying from 25% to 58%[51,53,54].
Some authors have reported that the presence of multiple nodules is an independent risk factor of recurrence after liver resection[37,55].
Poon _et al_[56] reported a 5-year survival rate of 60% after liver resection in patients with less than 3 HCC nodules ≤ 3 cm. Ruzzenente _et al_[33] conducted a study on 464 HCC patients from a multi-institutional database and found that patients with less than 3 nodules who underwent liver resection had a higher survival rate than those who were treated with local ablative therapies (including percutaneous ablation and TACE) with a median survival of 58 and 20 mo (P < 0.01), respectively. These data were confirmed by a subsequent randomised control trial. In patients with multifocal HCC meeting Milan Criteria, the authors reported a 5-year survival rate after liver resection and radiofrequency ablation of 69% and 45% (P = 0.042), respectively[57].
Furthermore, a Japanese nationwide survey reported that liver resection has an advantage over local ablative therapies because it can prevent recurrence in individuals with less than 3 HCC nodules that are ≤ 3 cm[58]. Liver resection also appears to provide better long-term survival than percutaneous ablation in patients with less than 3 HCC nodules that are > 3 cm[11].
In selected patients with multinodular BCLC B (more than 3 nodules) HCC and preserved liver function, liver resection yielded better long-term results than TACE with 5-year survival rates of 36%-37% and 11%-14%, respectively[29,59]. The results of liver resection in patients with multiple HCCs are shown in Table 1.
Although further studies are needed to confirm these results, liver resection seems to offer satisfactory long-term result in patients with multiple HCCs, especially for patients with small oligonodular HCCs.
BCLC B LARGE HCC (RECOMMENDED TACE)
There is no a univocal definition of “large” HCC in the BCLC classification. In the first algorithm proposed in 1999, a single nodule greater than 5 cm was considered BCLC B, but this in subsequent updates[12,21,24]. Tumour size is not a clear limiting factor for liver resection, but it remains an important prognostic factor likely because the incidence of macrovascular invasion and distant metastases is related to size[60]. Furthermore many patients with large HCC should undergo major hepatectomy, which is considered a high-risk procedure especially in cirrhotic patients[21,22]. Nevertheless, recent surgical series indicate that over 20% of patient with large HCCs (> 5 cm) are treated with surgical resection[33,25].
In the last decades, with improvements in surgical techniques and careful preoperative evaluation, the short-term results for patients with large HCCs have been similar to patients with smaller tumours, with mortality rates from 3% to 5% and morbidity from 30%-35%[61,62] (Table 1).
In the literature, the 5-year survival rates after liver resection ranges from 29% to 53%[33,63] for HCC nodules > 5 cm and 27% to 35% for nodules ≥ 10 cm[64,65]. A recent paper comparing liver resection to TACE in over 350 HCC BCLB B patients demonstrated that surgery is as safe as TACE and results in better overall survival. In particular, the 5-year overall survival rates for patients with a single large HCC nodule (mean size 8.8 cm) was 41% and 18%, in the liver resection and TACE groups, respectively (P < 0.01)[29] (Table 1).
In patients with large HCC, in which the presence of negative prognostic factors is frequent, the indication for preoperative TACE should be to improve the results of surgical resection. However, recent data did not show a survival benefit in the use of the combined approach preoperative TACE + surgery compared to surgery alone in patients with resectable large HCC[66,67].
Recently, metabolic syndrome related liver disease has been increasingly identified as a risk factor for HCC[4,5,68]. HCCs associated with metabolic syndrome are larger, frequently more well differentiated and arise in a less fibrotic liver than HCCs associated with cirrhosis[69].
Therefore, liver resection in patients with large HCCs and preserved liver function is likely to increase in patients with metabolic syndrome.
BCLC C HCC WITH MACROVASCULAR INVASION (RECOMMENDED SORAFENIB)
Macrovascular invasion (MVI) is one of the strongest predictors of survival in patients with HCC because it is related to an increased risk of intrahepatic or extrahepatic metastases[70,71]. The incidence of portal vein tumour thrombosis (PVTT) and hepatic veins invasion (HVI) reached 62% and 26%, respectively, in an autopsy series, and 5%-15% and 3%-4%, respectively in surgical series[32,72-74]. The resection of HCCs with macrovascular invasion is technically challenging with limited survival benefit. However, surgical resection has a higher survival rate than nonsurgical strategies or best supportive care[32,33]. The median survival of untreated HCC with PVTT and HVI are 2.7 and 5 mo, respectively[75,76]. The reported survival of these patients after Sorafenib treatment is 6 mo[77].
In recent surgical series including HCC patients with MVI, the postoperative mortality and morbidity ranges from 3.4% to 7.7% and from 30.8% to 37.1%, respectively[32,78,79]. In a multicentric study on 102 HCC patients with MVI treated by surgical resection, Pawlik et al. reported a 5-year survival rate of 10%[3]. In our surgical series published by Ruzzenente _et al_[33], the median survival after liver resection for patients with HCC and MVI was 10 mo with a 5-year survival rate of 20% (Table 1).
In the literature, better survival rates are reported for selected patients with PVTT, with a 5-year survival rate ranging from 11% to 42%[79-82]. In PVTT cases, two different surgical techniques have been reported with similar short- and long-term outcomes[79]. One is the anatomical en-block resection of the liver segment involved and portal vein bifurcation with or without the main trunk[80]. The other is thrombectomy using the peeling-off technique[83].
Recently, Chok _et al_[79] described the following three approaches for patients with PVTT based on the extension of the tumour thrombosis: group 1, HCC with ipsilateral PVTT resected in a hepatectomy; group 2, HCC with PVTT extending to or beyond the portal vein bifurcation, treated by en bloc resection followed by portal vein reconstruction; group 3, PVTT extending to or beyond the portal vein bifurcation, treated by thrombectomy.
The short and long-term results were similar among the three groups with a 5-year overall survival rate of 11.2%, 12.5% and 14.3%, respectively[79].
The reported survival after surgery for HCC patients with HVI or with caval invasion is approximately 13% at 5 years with a median survival of 9-19 mo[76,84].
PREOPERATIVE EVALUATION
The expansion of the indications for liver resection in HCC patients increases the risk of post-hepatectomy liver failure (PHLF) with a subsequent increase in postoperative morbidity and mortality[85]. PHLF is closely related to the volume and function of the remnant liver, and these two variables are the major determinants of the adequacy of the future remnant liver (FRL) after resection[86]. Thus, a meticulous preoperative assessment that includes an evaluation of liver volume and the function of the remnant liver is crucial before liver resection, especially in cirrhotic patients beyond the BCLC recommendations[87].
Liver function assessment includes conventional liver function tests (laboratory parameters), scoring systems (Child-Pugh and MELD) and qualitative tests (99-TC-GSA scintigraphy, indocyanine green test, MEGX and LiMAX). Of the proposed qualitative tests, the indocyanine green (ICG) test is considered the most powerful predictive test of operative mortality after a liver resection[88,89]. The 15 min ICG retention rate (ICGR15) is also the most frequently used parameter in the decision-making protocol before hepatectomy in Western countries. There is no clear consensus on the cut-off value of ICG retention with a predictive value of postoperative hepatic insufficiency, but an ICGR15 equal or greater than 14% is indicative of inadequate clearance with limited hepatic reserve[90,91].
Different methods of estimating liver volume have been introduced, and the two most frequently utilised in the literature are the 3-D volume computed tomography calculation and the calculation of standardised liver volume using body surface area or body weight[92,93]. According to the date in the literature, the FRL volume limit for safe liver resection in cirrhotic patients is 30%-40%[87].
FUTURE PERSPECTIVES
Despite the technical improvements in diagnosis and treatment, the prognosis of HCC patients may differ widely among those with the same clinical and pathological features[26,94]. The survival of these patients is likely affected by the heterogeneity of the biological behaviour of tumour cells[95]. Many authors have studied the biological processes that leads to the development of HCC and have discovered that the main signal transduction pathways include PI3K/Akt/mTOR[96], Wnt/b-catenin[97], HGF/c-MET[98], and MAP/ERK/c-myc[99]. Researchers have identified several genes, including those involved in the pathways mentioned, whose altered expression has an influence on the prognosis of patients with HCC[100-103].
Pedica _et al_[104] reported that aberrant expression of c-myc affects the prognosis of HCC patients after liver resection; in particular, patients with amplified c-myc have a poorer prognosis than patients with normal c-myc levels (polysomic or disomic expression) with a 3-year survival rate of 35.7% and 65.2%, respectively.
Currently, a widely accepted molecular classification system for HCC is still not available. Future perspectives should include the identification of molecular panel able to classify different patients according to their expected survival. This molecular classification could suggest the tailored type of treatment including new target therapies.
CONCLUSION
Recent improvements in surgical techniques and perioperative care have enhanced the feasibility and safety of liver resection with satisfactory long-term results in selected patients with early HCC with PH and with intermediate-advanced HCC. Currently, based on the BCLC algorithm, the EASL/AASLD guidelines exclude many patients from curative treatment, although they may benefit from liver resection. Nowadays, no other HCC classification proposed has been approved worldwide and the treatment strategy should be tailored on the single patient, based on literature data. Thus, a revision of the BCLC algorithm and clinical guidelines should be introduced possibly including new molecular classifications.
Footnotes
P- Reviewers: Aravalli RN, Niu ZS, Yang J S- Editor: Qi Y L- Editor: A E- Editor: Zhang DN
References
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. [PubMed] [DOI] [Cited in This Article: ]
7.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43. [PubMed] [DOI] [Cited in This Article: ]
8.
Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322-330. [PubMed] [DOI] [Cited in This Article: ]
9.
Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790-79; discussion 790-79;. [PubMed] [DOI] [Cited in This Article: ]
13.
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751-755. [PubMed] [DOI] [Cited in This Article: ]
14.
Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760-1769. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 426] [Cited by in F6Publishing: 438] [Article Influence: 19.0] [Reference Citation Analysis (0)]
16.
Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol. 1999;31:133-141. [PubMed] [DOI] [Cited in This Article: ]
17.
Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54:419-425. [PubMed] [DOI] [Cited in This Article: ]
18.
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711. [PubMed] [DOI] [Cited in This Article: ]
19.
Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PubMed] [DOI] [Cited in This Article: ]
21.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PubMed] [DOI] [Cited in This Article: ]
23.
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PubMed] [DOI] [Cited in This Article: ]
24.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PubMed] [DOI] [Cited in This Article: ]
25.
Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013;257:929-937. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 333] [Cited by in F6Publishing: 395] [Article Influence: 32.9] [Reference Citation Analysis (0)]
26.
Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56:412-418. [PubMed] [DOI] [Cited in This Article: ]
28.
Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212-220. [PubMed] [DOI] [Cited in This Article: ]
30.
Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 2001;233:379-384. [PubMed] [DOI] [Cited in This Article: ]
32.
Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403-410. [PubMed] [DOI] [Cited in This Article: ]
34.
Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg. 2007;205:108-123. [PubMed] [DOI] [Cited in This Article: ]
35.
Capussotti L, Ferrero A, Viganò L, Polastri R, Tabone M. Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines. Eur J Surg Oncol. 2009;35:11-15. [PubMed] [DOI] [Cited in This Article: ]
37.
Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, Hsia CY, Lui WY, King KL, Lee SD. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery. 2012;152:809-820. [PubMed] [DOI] [Cited in This Article: ]
41.
Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240:698-708; discussion 708-10. [PubMed] [DOI] [Cited in This Article: ]
47.
Duan C, Liu M, Zhang Z, Ma K, Bie P. Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. World J Surg Oncol. 2013;11:190. [PubMed] [DOI] [Cited in This Article: ]
51.
Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908-1916. [PubMed] [DOI] [Cited in This Article: ]
52.
Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fabbro D, Spinelli A, Botea F, Montorsi M. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg. 2008;143:1082-1090. [PubMed] [DOI] [Cited in This Article: ]
53.
Utsunomiya T, Shimada M, Taguchi KI, Hasegawa H, Yamashita Y, Hamatsu T, Aishima SI, Sugimachi K. Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma. J Am Coll Surg. 2000;190:331-335. [PubMed] [DOI] [Cited in This Article: ]
54.
Capussotti L, Muratore A, Amisano M, Polastri R, Bouzari H, Massucco P. Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival--a European single center experience. Eur J Surg Oncol. 2005;31:986-993. [PubMed] [DOI] [Cited in This Article: ]
55.
Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330-339. [PubMed] [DOI] [Cited in This Article: ]
56.
Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373-382. [PubMed] [DOI] [Cited in This Article: ]
58.
Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589-594. [PubMed] [DOI] [Cited in This Article: ]
61.
Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg. 2002;194:592-602. [PubMed] [DOI] [Cited in This Article: ]
64.
Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, Belghiti J, Ng IO, Yamaoka Y. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005;140:450-47; discussion 457-458. [PubMed] [DOI] [Cited in This Article: ]
67.
Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30:166-174. [PubMed] [DOI] [Cited in This Article: ]
68.
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533-539. [PubMed] [DOI] [Cited in This Article: ]
70.
Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. The Liver Cancer Study Group of Japan. Cancer. 1994;74:2772-2780. [PubMed] [DOI] [Cited in This Article: ]
71.
Kanda M, Tateishi R, Yoshida H, Sato T, Masuzaki R, Ohki T, Imamura J, Goto T, Yoshida H, Hamamura K. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008;28:1256-1263. [PubMed] [DOI] [Cited in This Article: ]
72.
Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990;211:277-287. [PubMed] [DOI] [Cited in This Article: ]
74.
Florman S, Weaver M, Primeaux P, Killackey M, Sierra R, Gomez S, Haque S, Regenstein F, Balart L. Aggressive resection of hepatocellular carcinoma with right atrial involvement. Am Surg. 2009;75:1104-1108. [PubMed] [DOI] [Cited in This Article: ]
75.
Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67. [PubMed] [DOI] [Cited in This Article: ]
77.
Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis. 2013;45:408-413. [PubMed] [DOI] [Cited in This Article: ]
80.
Wu CC, Hsieh SR, Chen JT, Ho WL, Lin MC, Yeh DC, Liu TJ, P’eng FK. An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation. Arch Surg. 2000;135:1273-1279. [PubMed] [DOI] [Cited in This Article: ]
81.
Inoue Y, Hasegawa K, Ishizawa T, Aoki T, Sano K, Beck Y, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery. 2009;145:9-19. [PubMed] [DOI] [Cited in This Article: ]
83.
Yamaoka Y, Kumada K, Ino K, Takayasu T, Shimahara Y, Mori K, Tanaka A, Morimoto T, Taki Y, Washida M. Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein. World J Surg. 1992;16:1172-116; discussion 1177. [PubMed] [DOI] [Cited in This Article: ]
84.
Le Treut YP, Hardwigsen J, Ananian P, Saïsse J, Grégoire E, Richa H, Campan P. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10:855-862. [PubMed] [DOI] [Cited in This Article: ]
85.
Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, Blumgart LH, Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325-330. [PubMed] [DOI] [Cited in This Article: ]
87.
Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg. 2012;29:6-17. [PubMed] [DOI] [Cited in This Article: ]
88.
Hemming AW, Scudamore CH, Shackleton CR, Pudek M, Erb SR. Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg. 1992;163:515-518. [PubMed] [DOI] [Cited in This Article: ]
89.
Nonami T, Nakao A, Kurokawa T, Inagaki H, Matsushita Y, Sakamoto J, Takagi H. Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Hepatogastroenterology. 1999;46:1669-1672. [PubMed] [DOI] [Cited in This Article: ]
90.
Lam CM, Fan ST, Lo CM, Wong J. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. Br J Surg. 1999;86:1012-1017. [PubMed] [DOI] [Cited in This Article: ]
92.
Ogasawara K, Une Y, Nakajima Y, Uchino J. The significance of measuring liver volume using computed tomographic images before and after hepatectomy. Surg Today. 1995;25:43-48. [PubMed] [DOI] [Cited in This Article: ]
93.
Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G, Hawkins IF. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127:512-519. [PubMed] [DOI] [Cited in This Article: ]
94.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576. [PubMed] [DOI] [Cited in This Article: ]
95.
Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252-257. [PubMed] [DOI] [Cited in This Article: ]
96.
Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-183, 1983.e1-11. [PubMed] [DOI] [Cited in This Article: ]
97.
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469-480. [PubMed] [DOI] [Cited in This Article: ]
98.
Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009;19:542-551. [PubMed] [DOI] [Cited in This Article: ]
99.
Chan KL, Guan XY, Ng IO. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol. 2004;35:1324-1331. [PubMed] [DOI] [Cited in This Article: ]
100.
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. [PubMed] [DOI] [Cited in This Article: ]
101.
Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012;36:e294-e299. [PubMed] [DOI] [Cited in This Article: ]